sprite-preloader
Anzeige
Mehr »
Mittwoch, 22.11.2017 Börsentäglich über 12.000 News von 570 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: 883035 ISIN: US8816242098 Ticker-Symbol: TEV 
Aktie:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
1-Woche-Intraday-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
11,321
11,366
21.11.
11,223
11,476
21.11.
16.09.2017 | 05:33
(67 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

IRVINE, CA / ACCESSWIRE / September 15, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Investors who purchased or otherwise acquired shares between November 15, 2016 and August 2, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the October 23, 2017 lead plaintiff motion deadline.

If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP


© 2017 ACCESSWIRE